ABCC1 and ovarian carcinoma: One research group has described using an ABCC1 small molecule inhibitor in combination with a glutathione-depleting drug to explore cellular viability and chemosensitization in SKOV3 ovarian cancer cells where combination treatment displayed a loss of viability [36].